Idhifa® (enasidenib)
for Leukemia

Idhifa (enasidenib) treats acute myeloid leukemia (AML) in adults with a specific IDH2 gene mutation. This mutation prevents blood cells from maturing normally. Idhifa helps bone marrow produce healthy blood cells, reducing the need for transfusions. It’s used when AML returns or hasn't improved after previous treatments.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia